Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Notes Payables (2016 - 2021)

BioRestorative Therapies (BRTX) has disclosed Notes Payables for 11 consecutive years, with $250000.0 as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Notes Payables changed N/A year-over-year to $250000.0, compared with a TTM value of $250000.0 through Dec 2021, changed N/A, and an annual FY2021 reading of $250000.0, changed N/A over the prior year.
  • Notes Payables was $250000.0 for Q4 2021 at BioRestorative Therapies, down from $5.9 million in the prior quarter.
  • Across five years, Notes Payables topped out at $8.0 million in Q1 2020 and bottomed at $250000.0 in Q4 2021.
  • Average Notes Payables over 5 years is $4.3 million, with a median of $4.0 million recorded in 2019.
  • The sharpest move saw Notes Payables skyrocketed 138.82% in 2019, then tumbled 41.08% in 2021.
  • Year by year, Notes Payables stood at $3.5 million in 2017, then rose by 4.56% to $3.6 million in 2018, then soared by 97.09% to $7.1 million in 2019, then grew by 12.26% to $8.0 million in 2020, then crashed by 96.88% to $250000.0 in 2021.
  • Business Quant data shows Notes Payables for BRTX at $250000.0 in Q4 2021, $5.9 million in Q3 2021, and $5.0 million in Q2 2021.